Wall Street analysts expect Qiagen NV (NYSE:QGEN) to post sales of $382.16 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Qiagen’s earnings. The lowest sales estimate is $379.69 million and the highest is $384.63 million. Qiagen reported sales of $363.98 million in the same quarter last year, which would suggest a positive year over year growth rate of 5%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, November 5th.
On average, analysts expect that Qiagen will report full year sales of $1.52 billion for the current year, with estimates ranging from $1.52 billion to $1.53 billion. For the next financial year, analysts anticipate that the business will report sales of $1.64 billion, with estimates ranging from $1.62 billion to $1.66 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Qiagen.
Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, July 31st. The company reported $0.33 EPS for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.01. The business had revenue of $377.20 million for the quarter, compared to analyst estimates of $376.89 million. Qiagen had a return on equity of 12.22% and a net margin of 5.26%.
QGEN has been the topic of a number of research analyst reports. ValuEngine upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Morgan Stanley increased their price target on Qiagen from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 1st. Citigroup increased their price target on Qiagen from $35.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, August 2nd. Bank of America increased their price target on Qiagen from $38.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, August 2nd. Finally, Deutsche Bank restated a “buy” rating on shares of Qiagen in a research report on Friday, August 3rd. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Qiagen currently has an average rating of “Buy” and an average price target of $40.40.
NYSE QGEN opened at $35.66 on Tuesday. The company has a market cap of $8.65 billion, a P/E ratio of 28.11, a price-to-earnings-growth ratio of 2.34 and a beta of 1.10. Qiagen has a one year low of $30.20 and a one year high of $39.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.62 and a current ratio of 1.79.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.